Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

Core Viewpoint - aTyr Pharma, Inc. experienced a dramatic decline in share price, dropping over 80% after failing to meet the primary endpoint in its late-stage study of efzofitimod for pulmonary sarcoidosis treatment [1][7]. Company Summary - On September 15, 2025, aTyr announced that its EFZO-FIT trial did not achieve statistical significance in steroid reduction after a year of tapering, leading to a significant market reaction [7]. - The company had previously assured investors that its Phase 2 data was among the best seen by experts and highlighted a multi-billion-dollar market opportunity for efzofitimod [6]. Investigation Summary - Following the market reaction, Hagens Berman, a national shareholders rights firm, initiated an investigation into whether aTyr misled investors regarding its Phase 2 data and Phase 3 trial design [2][5]. - The investigation is focused on the accuracy of aTyr's disclosures about the quality of its Phase 2 data and the design of the EFZO-FIT trial [5]. Market Reaction - The announcement of the topline results led to a flood of analyst downgrades and a catastrophic drop in aTyr's share price, reflecting investor disappointment and loss of confidence [7].

Core Insights - The Phase 3 EFZO-FIT™ study of efzofitimod demonstrated clinical benefits in patients with pulmonary sarcoidosis, particularly in improving fatigue and general health scores at week 48 compared to placebo [2][3][4] - Despite not meeting the primary endpoint of reducing mean daily oral corticosteroid dose, efzofitimod showed potential to improve multiple disease-related health outcomes, including cough, shortness of breath, and fatigue [3][4] Company Overview - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [2][9] - The company is investigating efzofitimod, a biologic immunomodulator, for treating interstitial lung disease (ILD), which includes pulmonary sarcoidosis and systemic sclerosis-related ILD [8][9] Study Findings - The study involved 268 patients and presented significant improvements in the Fatigue Assessment Scale Total Score (p=0.0226) and King's Sarcoidosis Questionnaire-General Health score (p=0.0197) for the 5.0 mg/kg efzofitimod treatment group [2][3][4] - Additional outcomes included a trend towards a greater proportion of patients achieving steroid-free status for at least six months and improvements in KSQ-Lung score [3][4] Treatment Context - Pulmonary sarcoidosis affects approximately 200,000 Americans, with current treatments primarily involving corticosteroids, which have limited efficacy and significant side effects [6][7] - Efzofitimod aims to provide a safer and more effective treatment option for patients with pulmonary sarcoidosis, potentially reducing reliance on chronic steroids [3][8]

Core Insights - aTyr Pharma, Inc. experienced a significant drop in share price, over 80%, following the announcement that its late-stage study of efzofitimod for pulmonary sarcoidosis did not meet its primary endpoint [1][5] Company Developments - The company reported that the topline results of the EFZO-FIT trial failed to achieve statistical significance in steroid reduction after a year of forced tapering, with placebo tapering outperforming the company's projections [5] - aTyr had previously assured investors that its Phase 2 data was among the best seen by experts and emphasized a multi-billion-dollar market opportunity for efzofitimod [4] Market Reaction - Following the disappointing trial results, the market reacted sharply, leading to a significant decline in aTyr's share price and prompting numerous analyst downgrades [5] Legal Investigation - Hagens Berman, a national shareholders rights firm, has initiated an investigation into whether aTyr misled investors regarding the Phase 2 data and the design of the Phase 3 EFZO-FIT trial [2][6] - The firm is encouraging investors who suffered losses to come forward and is seeking information from individuals who may assist in the investigation [2][6]

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether aTyr and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On September 15, 2 ...

Core Insights - aTyr Pharma, Inc. experienced a dramatic decline in share price, dropping over 80% after failing to meet the primary endpoint in its late-stage study of efzofitimod for pulmonary sarcoidosis [1][5] Company Performance - The topline results from the EFZO-FIT trial indicated that the primary goal of steroid reduction was not achieved, with placebo tapering outperforming the company's expectations [5] - aTyr previously claimed that its Phase 2 data was among the best seen by experts and highlighted a multi-billion-dollar market opportunity for efzofitimod [4] Market Reaction - Following the disappointing trial results, the market reacted severely, leading to a significant drop in share price and numerous analyst downgrades [5] Legal Investigation - Hagens Berman, a national shareholders rights firm, has initiated an investigation into aTyr for potentially misleading investors regarding the Phase 2 data and the design of the Phase 3 trial [2][6] - The investigation is focused on the accuracy of aTyr's disclosures and the implications of the failed trial results on investor expectations [3][6]

Core Insights - The health care sector has several oversold stocks that present buying opportunities for undervalued companies [1] - The Relative Strength Index (RSI) is a key indicator for identifying oversold conditions, typically below 30 [1] Company Summaries - **Boston Scientific Corp (BSX)**: Upgraded from Perform to Outperform by Oppenheimer analyst Steven Lichtman, with a price target raised from $118 to $125. The stock has a 52-week low of $80.64 and an RSI value of 27.3. Recent price action shows a 0.3% decline, closing at $98.23 [7] - **aTyr Pharma Inc (ATYR)**: Announced that its Phase 3 EFZO-FIT study did not meet its primary endpoint, leading to an 80% stock decline over five days. The stock has a 52-week low of $0.97 and an RSI value of 22.6. Recent price action shows a 2.4% gain, closing at $1.05 [7] - **Reviva Pharmaceuticals Holdings Inc (RVPH)**: Announced a $9 million public offering, resulting in a 21% decline over the past month. The stock has a 52-week low of $0.30 and an RSI value of 24.5. Recent price action shows a 3.7% gain, closing at $0.42 [7]

Core Insights - aTyr Pharma's Phase 3 trial of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint but showed encouraging results for patients [1][2] - The trial involved 268 patients across the U.S., Europe, Japan, and Brazil, indicating potential benefits in steroid withdrawal and quality of life improvements [2] - The Foundation for Sarcoidosis Research (FSR) emphasizes the importance of patient perspectives in future research and drug development [3][4] Company Insights - aTyr Pharma is a clinical stage biotechnology company focused on developing therapies for fibrosis and inflammation, with efzofitimod as its lead candidate [8] - The company plans to consult with the FDA regarding future options for efzofitimod, highlighting its commitment to patient-centered outcomes [4][5] Industry Insights - Sarcoidosis is a rare inflammatory disease affecting approximately 175,000 people in the U.S., with 90% of patients experiencing lung involvement [6] - There is a significant unmet need for effective treatments in this underserved population, underscoring the importance of ongoing research and development [5][6]

Core Viewpoint - aTyr Pharma, Inc. experienced a significant decline in share price, dropping over 80% following the announcement that its late-stage study of efzofitimod for pulmonary sarcoidosis did not achieve its primary endpoint [1] Company Summary - The company reported on September 15, 2025, that its clinical trial for efzofitimod, aimed at treating pulmonary sarcoidosis, failed to meet its main goal [1] - This failure in the late-stage study has led to a drastic decrease in investor confidence, reflected in the sharp decline in share price [1] Industry Summary - The incident highlights the volatility and risks associated with clinical trials in the biopharmaceutical industry, particularly for companies developing treatments for interstitial lung diseases [1] - The failure of a late-stage study can have immediate and severe financial implications for companies in this sector, affecting stock performance and investor sentiment [1]

Company Overview - aTyr Pharma, Inc. experienced a significant decline in share price, dropping over 80% following the announcement that its late-stage study of efzofitimod for pulmonary sarcoidosis did not meet its primary endpoint [1][5]. Market Reaction - The market reacted severely to the topline results call on September 15, 2025, where aTyr reported that the trial failed to achieve statistical significance in steroid reduction, with placebo tapering outperforming the company's expectations [5]. Investigation Details - Hagens Berman, a national shareholders rights firm, has initiated an investigation into aTyr for potentially misleading investors regarding the Phase 2 data and the design of the Phase 3 EFZO-FIT™ trial [2][6]. - The investigation is focused on the accuracy of aTyr's disclosures about the quality of its Phase 2 efzofitimod data and the trial design [3][6]. Company Claims - aTyr previously assured investors that its Phase 2 data was among the best seen by experts and claimed that efzofitimod could dominate the ILD market, which was described as a multi-billion-dollar opportunity [4][6].